On the other hand, baricitinib, a high-affinity JAK1/2 inhibitor, has been shown to improve some clinical and laboratory parameters (including C-reactive protein levels) in a pilot study of COVID-19 cases (Cantini et al., 2020). The gene discussed is JAK1; the disease is COVID-19.